Argenx Nv Adr Stock Today
| ARGX Stock | USD 614.59 7.43 1.22% |
Performance11 of 100
| Odds Of DistressLess than 31
|
Argenx NV is trading at 614.59 as of the 28th of November 2024; that is 1.22% increase since the beginning of the trading day. The stock's open price was 607.16. Argenx NV has about a 31 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for argenx NV ADR are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of May 2017 | Category Healthcare | Classification Health Care |
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. The company has 59.8 M outstanding shares of which 1.7 M shares are presently shorted by private and institutional investors with about 7.51 trading days to cover. More on argenx NV ADR
Moving together with Argenx Stock
| 0.63 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Argenx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Argenx Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | MSc EMBA | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, ARCA Biotechnology, BEL-20 INDEX, BEL All Share, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsArgenx NV can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Argenx NV's financial leverage. It provides some insight into what part of Argenx NV's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
argenx NV ADR (ARGX) is traded on NASDAQ Exchange in USA. It is located in Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB and employs 1,148 people. Argenx NV is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 36.79 B. argenx NV ADR conducts business under Biotechnology sector and is part of Health Care industry. The entity has 59.8 M outstanding shares of which 1.7 M shares are presently shorted by private and institutional investors with about 7.51 trading days to cover.
argenx NV ADR currently holds about 2.6 B in cash with (420.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 47.17.
Check Argenx NV Probability Of Bankruptcy
Ownership AllocationArgenx NV holds a total of 59.8 Million outstanding shares. Over half of Argenx NV's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Argenx Ownership Details
Argenx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2024-09-30 | 614.9 K | |
| Clearbridge Advisors, Llc | 2024-09-30 | 589.5 K | |
| Paradigm Biocapital Advisors Lp | 2024-09-30 | 480.4 K | |
| Wellington Management Company Llp | 2024-06-30 | 426.7 K | |
| Sei Investments Co | 2024-06-30 | 381.5 K | |
| Deep Track Capital, Lp | 2024-09-30 | 365 K | |
| Alkeon Capital Management, Llc | 2024-09-30 | 345 K | |
| Pictet Asset Manangement Sa | 2024-06-30 | 308.2 K | |
| Bank Of America Corp | 2024-06-30 | 290.2 K | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 5.6 M | |
| Fmr Inc | 2024-09-30 | 4.8 M |
Argenx NV Historical Income Statement
Argenx Stock Against Markets
Argenx NV Corporate Management
| Karen Massey | Chief Officer | Profile | |
| Beth DelGiacco | VP Relations | Profile | |
| EMBA MBA | CEO Director | Profile | |
| Filip Borgions | VP Operations | Profile | |
| Arjen MSc | Vice Strategy | Profile | |
| Karl Gubitz | Chief Officer | Profile | |
| Luc Truyen | Chief Officer | Profile |
Already Invested in argenx NV ADR?
The danger of trading argenx NV ADR is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Argenx NV is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Argenx NV. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile argenx NV ADR is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Argenx Stock Analysis
When running Argenx NV's price analysis, check to measure Argenx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argenx NV is operating at the current time. Most of Argenx NV's value examination focuses on studying past and present price action to predict the probability of Argenx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argenx NV's price. Additionally, you may evaluate how the addition of Argenx NV to your portfolios can decrease your overall portfolio volatility.